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Abstract
Background: Our hypothesis was that both the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) and
Modification of Diet in Renal Disease (MDRD) equations would underestimate directly measured GFR (mGFR) to a
similar extent in people with diabetes and preserved renal function.
Methods: In a cross-sectional study, bias (eGFR – mGFR) was compared for the CKD-EPI and MDRD equations, after
stratification for mGFR levels. We also examined the ability of the CKD-EPI compared with the MDRD equation to
correctly classify subjects to various CKD stages. In a longitudinal study of subjects with an early decline in GFR i.e.,
initial mGFR >60 ml/min/1.73 m2 and rate of decline in GFR (ΔmGFR) > 3.3 ml/min/1.73 m2 per year, ΔmGFR (based
on initial and final values) was compared with ΔeGFR by the CKD-EPI and MDRD equations over a mean of 9 years.
Results: In the cross-sectional study, mGFR for the whole group was 80 ± 2.2 ml/min/1.73 m2 (n = 199, 75 % type 2
diabetes). For subjects with mGFR >90 ml/min/1.73 m2 (mGFR: 112 ± 2.0, n = 76), both equations significantly
underestimated mGFR to a similar extent: bias for CKD-EPI: -12 ± 1.4 ml/min/1.73 m2 (p < 0.001) and for MDRD: -11 ±
2.1 ml/min/1.73 m2 (p < 0.001). Using the CKD-EPI compared with the MDRD equation did not improve the number of
subjects that were correctly classified to a CKD-stage. No biochemical or clinical patient characteristics were identified
to account for the under estimation of mGFR values in the normal to high range by the CKD-EPI equation. In the
longitudinal study (n = 30, 66 % type 1 diabetes), initial and final mGFR values were 102.8 ± 6 and 54.6 ± 6.0 ml/min/
1.73 m2, respectively. Mean ΔGFR (ml/min/1.73 m2 per year) was 6.0 by mGFR compared with only 3.0 by MDRD and
3.2 by CKD-EPI (both p < 0.05 vs mGFR)
Conclusions: Both the CKD-EPI and MDRD equations underestimate reference GFR values >90 ml/min/1.73 m2 as well
as an early decline in GFR to a similar extent in people with diabetes. There is scope to improve methods for
estimating an early decline in GFR.
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Background
It is well recognised that estimating GFR using the
Modification of Diet in Renal Disease (MDRD) equation
significantly underestimates reference GFR values in the
normal-high range in people with and without diabetes
[1]. In an attempt to overcome some of the limitations
of the MDRD equation, the Chronic Kidney Disease-
Epidemiology Collaboration (CKD-EPI) equation has
been developed, using the same variables as the MDRD
equation. In particular, it has been reported to reduce
bias compared to the MDRD equation for GFR > 60 ml/
min/1.73 m2 in various study populations [2, 3]. This re-
duction in bias has been attributed to the characteristics
of the populations from which the CKD-EPI and the
MDRD equations were derived, with the mean measured
GFR levels being 68 and 40 ml/min/1.73 m2 in these re-
spective populations [1, 4]. Unlike the MDRD equation,
the CKD-EPI equation also contains a spline term for
serum creatinine (at 62 μmol/L for females and
80 μmol/L for males) to account for the weaker relation-
ship between serum creatinine and GFR at lower com-
pared with higher creatinine levels [4, 5].
Despite the above, the CKD-EPI equation appears to
still significantly underestimate normal to high GFR
levels to a similar extent as the MDRD equation in
people with diabetes [6–9]. There is also evidence to
suggest that the CKD-EPI equation underperforms in
people with diabetes compared to those without diabetes
[10]. One of potential limitations of many of the above
studies that have assessed the performance of the CKD-
EPI equation in diabetes is that they have not included a
direct measurement of serum creatinine by an enzymatic
method, the accepted ideal method for measuring serum
creatinine. Furthermore, few previous studies have in-
cluded a longitudinal assessment of the bias observed
with estimating GFR by the CKD-EPI equation and
hence the ability of this method to accurately assess an
early decline in GFR. In people with diabetes, the rea-
sons for the apparent lack of improvement in the under-
estimation of reference GFR levels when an eGFR is
derived from the CKD-EPI compared with the MDRD
equation also remain unclear.
Given the above, our hypothesis was that the CKD-EPI
and MDRD equations would underestimate directly
measured GFR to a similar extent in people with dia-
betes who have GFR values in the normal to high range.
Therefore, the aim of this study was to compare the per-
formance of the CKD-EPI and MDRD equations in
people with diabetes for estimating directly measured
GFR (mGFR) values, when measurements of serum cre-
atinine are based on an enzymatic assay. Furthermore,
we examined the ability of the CKD-EPI compared with
the MDRD equation to correctly classify subjects to vari-
ous CKD stages. We also explored whether certain
clinical or biochemical characteristics of subgroups of
patients with diabetes influenced the performance of the
CKD-EPI equation. Finally, we assessed the ability of the
CKD-EPI equation to accurately monitor early longitu-
dinal changes in GFR.
Methods
Study population and design
Subjects involved in this study attended the diabetes
clinics at Austin Health, University of Melbourne affili-
ated tertiary referral centre. Initially, a cross-sectional
study of 199 consecutive patients who had an isotopic
GFR (mGFR) measurement was performed followed by a
separate longitudinal study of 30 patients with diabetes
that were identified as having an early decline in GFR
(rate of mGFR decline > 3.3 ml/min/1.73 m2 per year)
and who were followed for nine years [11, 12]. As previ-
ously described, this approach allowed us to follow a
group of patients whose renal function declined from a
normal-high GFR to subnormal mGFR (17). The rate of
decline in mGFR was based on the difference between
the first and last mGFR over the nine year interval.
Subjects with known non-diabetic renal disease were
excluded. A fasting blood sample was collected on the
morning of the mGFR estimation for the measurement
of glucose, electrolytes, glycated haemoglobin (HbA1c)
and lipid levels. The following clinical information was
recorded for all patients: age, gender, type and duration
of diabetes, height, weight, body mass index (BMI), albu-
min excretion rate (AER; average result of at least two
24-h urine collections), blood pressure and smoking his-
tory, history of retinopathy and history of any macrovas-
cular diseases classified as coronary artery disease,
stroke or peripheral vascular disease. The type of dia-
betes was classified according to World Health
Organization criteria. The research reported in the
manuscript was carried out according to the declaration
of Helsinki (2000) of the World Medical Association,
and was approved by the Human Research Ethics Com-
mittee of Austin Health. All participants provided writ-
ten consent.
Laboratory methods
The reference mGFR measurement was obtained using a
plasma decay technique for samples collected at 120,
165 and 210 min following a single bolus injection of
99mTc-diethylene-triamine-pentaacetic acid (DTPA). The
Brochner–Mortensen correction was then applied to the
decay results obtained by this single bolus injection dis-
appearance method [13, 14]. Plasma glucose, electro-
lytes, lipids, HbA1c levels and urinary albumin were
measured as described previously [15].
Creatinine in the cross-sectional analysis was mea-
sured with the Roche enzymatic assay which is traceable
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to the Isotope Dilution Mass Spectrometry (IDMS)
method as described previously. The longitudinal study
was based on an analysis of serum creatinine levels that
were recorded in a clinic database where creatinine
levels had been measured by the modified Jaffe reaction
on a Hitachi 911 automatic analyser (Roche Diagnostics,
Mannheim, Germany). The intra-assay coefficient of
variation (CV) was 2.3 % at a creatinine concentration of
67.1 mol/L for this assay. There was an excellent linear
correlation between all 199 sample assayed by the en-
zymatic method for the cross sectional analysis and the
above Jaffe method (y = 0.953x + 0.767, r2 = 0.965) across
a wide range (25 to 250 mmol/L) of creatinine values.
However, creatinine values assayed by the enzymatic
method were slightly lower compared to the Jaffe
method. The creatinine values used for the longitudinal
analysis were therefore directly calibrated with the en-
zymatic method based on the ratio of creatinine values
measured by both the Jaffe and enzymatic methods. In
the 199 serum samples from the cross-sectional analysis
we derived a recalibrated enzymatic creatinine value
that = 0.961 × Jaffe measured creatinine.
Estimations of GFR based on serum creatinine were
derived from the “175” MDRD equation and the CKD-
EPI equation as outlined below-
The adjusted “175” MDRD-4 variable equation (for cre-
atinine measurements traceable to the IDMS method )
i.e., eGFR = 175 × [(Scr × 0.0113)
-1.154] × (age)-0.203 × (0.742
if female) × (1.212 if African-American).
The CKD-EPI equation i.e., eGFR = 141 ×min(Scr ×
0.0113/k, 1)α ×max(Scr × 0.0113/k, 1)-1.209 × 0.993Age ×
1.018 [if female] × 1.159 [if black], where Scr is serum cre-
atinine, k is 0.7 for females and 0.9 for males, α is -0.329
for females and -0.411 for males, min indicates the mini-
mum of Scr/k or 1, and max indicates the maximum of
Scr/k or 1.
Statistical analysis
The agreement between mGFR and eGFR (derived from
either the MDRD or CKD-EI equations) was estimated
using the Concordance Correlation Coefficient (rho_c)
which measures both precision and accuracy to deter-
mine how far the difference between the observed data
deviate from the line of perfect concordance [16]. When
describing the strength of agreement, according to the
commonly adopted classification, a rho_c <0 = poor
agreement, 0-0.2 = slight, 0.21-0.4 = fair, 0.41-0.6 =mod-
erate, 0.61-0.8 = substantial and 0.81-1 = almost perfect
[17]. The Bland-Altman plot method was also used to
test the agreement between mGFR and an eGFR derived
from the MDRD or the CKD-EPI equations for the en-
tire study population in the cross-sectional analysis [18].
The performance of creatinine based eGFR equations
was also compared by assessment of bias (eGFR -
mGFR), so that bias is a negative value when eGFR un-
derestimates mGFR, accuracy (the proportion of results
falling within 15 % (P15) or 30 % (P30) of mGFR values)
and precision, expressed as standard deviation (SD) of
the bias [19]. In addition, the proportion of patients clas-
sified into the correct CKD stage according to mGFR
measurement by each prediction equation (MDRD or
CKD-EPI) was also determined. The proportion
correctly classified was calculated for the whole study
population as well as for each CKD stage separately
(stage 1: ≥ 90, stage 2: 60-89 and < stage 3: < 60 ml/min/
1.73 m2). Results are expressed as mean ± SD and statis-
tical analysis of continuous variables was performed
using ANOVA with the Tukey test for multiple compari-
sons or by unpaired t-tests where appropriate. Categor-
ical variables were compared using Chi-χ2 analysis. Data
confirmation for normality prior to statistical tests and
in conjunction with confidence intervals was performed
using the Shapiro Wilks test (Stata 13.1). A P-value of
0.05 was used in conjunction with all statistical tests to
distinguish significant outcomes or differences.
Results
Cross-sectional analysis
The characteristics of the study population used for the
cross sectional study (n = 199, 75 % type 2 diabetes), and
divided into strata of mGFR > 90 (n = 76), 60-90 (n = 63)
and < 60 (n = 60) ml/min/1.73 m2 are shown in Table 1.
As expected, patients with the highest mGFR levels were
younger and more likely to have type 1 diabetes, shorter
duration of diabetes, a lower AER, higher rate of nor-
moalbuminuria, lower systolic blood pressure and lower
rate of macrovascular complications than those with
lower mGFR levels. HbA1c and fasting blood glucose
levels were higher in patients with higher mGFR levels.
There were no differences in the rates of use of renin-
angiotensin inhibiting agents or fenofibrate, medications
known to alter creatinine or eGFR levels, in patients
with various mGFR levels.
Overall there was an excellent agreement between
mGFR and eGFR derived from the MDRD or CKD-EPI
equations as assessed by the concordance correlation co-
efficient as shown in Fig. 1a and b (MDRD: rho_c =0.841,
95 % CI 0.801-0.881 and CKD-EPI: rho_c =0.864, 95 % CI
0.832-0.828). There was no difference in the concordance
correlation coefficient for the MDRD or CKD-EPI equa-
tions for different CKD stages. However, the difference be-
tween mGFR and eGFR derived from either equation
increased proportionally to the magnitude of the mGFR,
indicative of proportional bias.
The mGFR for the entire cross sectional study group
was 80 ± 2.2 ml/min/1.73 m2. As shown in Fig. 1c and d,
Bland-Altman analysis revealed a bias of -1.60 ± 16.2 ml/
min/1.73 m2 with 95 % limits of agreement from -34.2
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to 30.9 between an eGFR derived from the MDRD equa-
tion and mGFR. For an eGFR derived from the CKD-
EPI equation, bias was -1.6 ± 14.6 ml/min/1.73 m2 with
95 % limits of agreement from -30.3 to 27.0. In the over-
all study population, precision (SD of the bias) was 14.6
versus 16.6 ml/min/1.73 m2 for the for the CKD-EPI
and MDRD equations, respectively and accuracy defined
by the proportion of results falling within 15 % or 30 %
of mGFR values for eGFR values was P(15) 58.3 % and
P(30) 90.5 % versus P(15) 51.3 % and P(30) 86.4 % for
the CKD-EPI versus MDRD equations, respectively. Al-
though precision and accuracy for eGFR values derived
from the CKD-EPI compared with the MDRD equation
were marginally better, these differences were not statis-
tically significant (Table 2).
As shown in Fig. 2a, for patients with mGFR
>90 ml/min/1.73 m2 (mGFR: 112 ± 17.4), both equa-
tions underestimated mGFR to a similar extent: bias
for CKD-EPI: -12.4 ± 12.2 ml/min/1.73 m2 (p < 0.001)
and for MDRD: -11.0 ± 18.3 ml/min/1.73 m2 (p < 0.001).
By contrast, for subjects with an mGFR < 90 ml/min/
1.73 m2, there was a non-significant trend for both equa-
tions to overestimate mGFR. Patients with mGFR >90 ml/
min/1.73 m2 were further stratified into those with
mGFR > 90-120 (n = 55) or > 120 ml/min/1.73 m2 (n = 21)
as shown in Fig. 2b. For patients with mGFR > 120 ml/
min/1.73 m2 there was a very large underestimation
of mGFR when eGFR values were derived from either
the CKD-EPI equation: - 23.1 ± 22.8 ml/min/1.73 m2
(p < 0.001) or from the MDRD equation: -16.0 ±
28.8 ml/min/1.73 m2 (p < 0.05).
For both MDRD and CKD-EPI equations, precision
tended to improve (smaller SD of the bias) as bias de-
creased for lower mGFR values. In contrast, accuracy as
measured by both P(15) and P(30) increased for eGFR
values derived from the CKD-EPI equation, but not the
Table 1 Patient characteristics for the cross-sectional analysis (n = 199). Values shown as mean ± SD or median (interquartile range)
and p values obtained from comparison between the 3 mGFR groups, calculated from a one-way ANOVA or χ2 test
Parameter All (n=199) mGFR <60 (n=60) mGFR 60-90 (n=63) mGFR >90 (n=76) p value
Age (Yr) 62.8 ± 12.7 70.9 ± 10.8 65.4 ± 9.2 54.3 ± 11.3 <0.001
Gender (% males) 67 65 65 70 0.79
Type diabetes (% T1/T2) 25/75 15/85 21/79 37/63 0.009
Duration of diabetes (Years) 18.0 ± 11.4 20.9 ± 12.0 19.1 ± 12.7 14.8 ± 8.9 0.007
Height (cm) 168.6 ± 9.3 167.5 ± 9.2 167.5 ± 9.6 170.5 ± 8.9 0.12
Weight (kg) 88.8 ± 21.1 85.8 ± 19.6 89.3 ± 24.5 90.7 ± 19.3 0.41
BMI (kg/m2) 31.1 ± 7.0 30.2 ± 6.0 31.8 ± 8.5 31.1 ± 6.1 0.46
mGFR (ml/min/1.73m2) 80.0 ± 30.9 44.2 ± 10.8 75.5 ± 9.8 111.8 ± 17.0 <0.001
MDRD (ml/min/1.73m2) 78.4 ± 28.2 48.2 ± 13.3 79.5 ± 17.5 100.8 ± 22.5 <0.001
CKD-EPI (ml/min/1.73m2) 78.4 ± 24.9 49.5 ± 14.2 80.7 ± 15.2 99.4 ± 13.1 <0.001
AER (μg/min) 10.4 (4.3, 26.3) 20.7 (7.6, 71.3) 5.8 (3.5, 19.1) 8.6 (4.3, 20.7) 0.47
AER (% normo/micro/macro) 69.2/24.7/6.1 54.2/32.2/13.6 69.8/23.8/6.4 80.3/19.7/0 0.004
HbA1C (%) 7.60 ± 1.1 7.35 ± 1.0 7.42 ± 0.085 7.94 ± 1.3 0.002
HbA1C (mmol/mole) 60 57 58 63 0.002
Systolic blood pressure (mmHg) 131.9 ± 14.6 135.2 ± 17.4 132.7 ± 15.2 128.7 ± 10.8 0.03
Diastolic blood pressure (mmHg) 71.4 ± 10.1 67.9 ± 9.6 72.2 ± 10.9 73.5 ± 9.2 0.005
Any blood pressure therapy (%) 81 88 82 76 0.21
ACE inhibitor therapy (%) 47 52 42 46 0.65
Lipid lowering therapy (%) 83 88 89 76 0.08
Fenofibrate therapy (%) 8 11 8 5 0.55
Retinopathy () 53 61 51 48 0.34
IHD (%) 31 39 38 19 0.02
CVD (%) 5 5 7 3 0.56
PVD (%) 13 25 12 4 0.002
History of macrovascular disease (%) 40 49 48 23 0.002
BMI Body Mass Index, mGFR measured Glomerular Filtration Rate, MDRD Modification of Diet in Renal Disease, CKD-EPI Chronic Kidney Disease-Epidemiology
Collaboration, AER Albumin Excretion Rate, Normo Normoalbuminuria, Micro Microalbuminuria, Macro Macroalbuminuria, HbA1c Glycated Haemoglobin, ACE
Angiotensin Converting Enzyme, IHD Ischaemic Heart Disease, CVD Cerebrovascular Disease, PVD Peripheral Vascular Disease
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MDRD equation, as mGFR values increased (Table 3). Fur-
thermore, for mGFR values > 90 ml/min/1.73 m2, the ac-
curacy (P(15)), was significantly greater for eGFR values
derived from the CKD-EPI compared with the MDRD
equation. There was no difference the ability of the MDRD
or CKD-EPI equations to correctly classify patients accord-
ing to their CKD stage determined by mGFR (Table 4).
The influence of clinical and biochemical characteristics
on the MDRD and CKD-EPI equations
The effects of age (≤60 or > 60 years), sex (male vs female),
BMI (≤30 or > 30 kg/m2), HbA1c (≤8 or > 8 % : ≤ 64 or > 64
mmole/mol), fasting plasma glucose (≤8 or > 8 mmol/L)
and type of diabetes (type 1 vs 2) on mGFR and eGFR
values derived from the CKD-EPI and the MDRD equa-
tions are shown in Fig. 3a-f. As expected, younger com-
pared with older patients (Fig. 3a, p < 0.001) and those with
higher compared with lower fasting glucose levels (Fig. 3e,
p < 0.01) had higher mGFR values. However, age, sex, BMI,
HbA1c, fasting serum glucose and type of diabetes had no
influence on the difference between eGFR values derived
from the MDRD or CKD-EPI equations.
Next we examined the effect of age, sex, BMI, HbA1c,
fasting serum glucose levels and type of diabetes on
eGFR values derived from the MDRD and CKD-EPI
equations across the different strata of mGFR. As shown
Fig. 1 Concordance between eGFR derived from the MDRD (Panel a) or CKD-EPI (Panel b) equations with mGFR in the entire study population (n = 199).
The reduced major axis (the actually agreement between eGFR and mGFR) is shown as the broken line and the line of perfect concordance, i.e., if there
was perfect agreement between mGFR and eGFR is shown by the solid line. Bland-Altman plots summarising the agreement of an eGFR derived from the
MDRD (Panel c) or CKD-EPI (Panel d) equations with mGFR in the entire study population (n= 199). The dotted lines show the average of the differences
between the GFR methods and the 95 % limits of agreement
Table 2 Bland-Altman results together with accuracy (the
proportion of results falling within 15 % or 30 % of mGFR
values) and precision (the SD of the bias) for eGFR values
derived from the MDRD or CKD-EPI equations with mGFR in
the entire study population (n = 199)
MDRD CKD-EPI
Bias -1.66 -1.60
SD 16.6 14.6
95 % Limits of agreement -34.2 to 30.9 -30.3 to 27.0
P(15) 51.3 % 58.3 %
P(30) 86.4 % 90.5 %
MDRD modification of diet in renal disease, CKD-EPI Chronic Kidney Disease-
Epidemiology Collaboration, mGFR measured glomerular filtration rate, SD
standard deviation, P(15) proportion of results falling within 15 % of mGFR
values, P(30) proportion of results falling within 30 % of mGFR values
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in Fig. 4b, eGFR levels estimated from the MDRD equa-
tion were significantly lower in males compared with fe-
males in the mGFR group > 90 ml/min/1.73 m2 but
gender was not related to eGFR levels for mGFR levels <
90 ml/min/1.73 m2. Gender was not related to eGFR de-
rived from the CKD-EPI equation. Age, BMI, HbA1c, fast-
ing plasma glucose levels or type of diabetes were not
related to eGFR derived from the MDRD or CKD-EPI
equations across the different strata of mGFR values
(Fig. 4a, c-f, respectively).
Longitudinal analysis
The clinical and biochemical characteristics of patients
used for the longitudinal study are shown in Table 5. Initial
and final mGFR values were 102.8 ± 6 and 54.6 ± 6.0 ml/
min/1.73 m2, respectively over 9 years of follow up. As
shown in Fig. 5, mean ΔGFR (ml/min/1.73 m2 per year)
was 6.0 by mGFR with estimates of GFR derived by the
MDRD or the CKD-EPI equations both significantly
underestimating the mGFR decline (ΔGFR 3.0 and 3.2 ml/
min/1.73 m2 per year, respectively, both p < 0.05 vs mGFR).
Discussion
We found that both the MDRD and CKD-EPI equations
provided an excellent estimation of mGFR in our entire
study population. However, our results confirm previous
findings which have shown that both the CKD-EPI and
MDRD equations significantly underestimate measured
GFR to a similar extent in people with diabetes when
mGFR is in the normal to high range [7, 8]. Furthermore,
Fig. 2 a eGFR values derived from the MDRD and CKD-EPI equations according to mGFR-stage 1 CKD: ≥ 90 (n = 60), stage 2 CKD : 60-89 (n = 63 )
and stage 3 CKD (n = 76) : < 60 ml/min/1.73 m2. b eGFR values derived from the MDRD and CKD-EPI equations according to mGFR values >90-
120 (n = 55) and > 120 (n = 21) ml/min/1.73 m2. * p < 0.05, *** p < 0.001 vs mGFR. mGFR: Measured Glomerular Filtration Rate, MDRD: Modification
of Diet in Renal Disease, CKD-EPI: Chronic Kidney Disease-Epidemiology Collaboration
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both equations were also found to significantly underesti-
mate a decline in mGFR values when a group of patients
were followed from normal to subnormal mGFR values
over 9 years.
The only advantage that we could demonstrate for the
CKD-EPI compared with the MDRD equation for esti-
mating mGFR in the normal to high range was an im-
provement in accuracy. The proportion of results falling
within 15 % of mGFR values > 90 ml/min/1.73 m2 was
significantly greater for eGFR values derived from the
CKD-EPI (70 %) compared with the MDRD (47 %) equa-
tion. Precision also tended be better (lower SD of the
bias) for the CKD-EPI compared to the MDRD equation
for mGFR values > 90 ml/min/1.73 m2. The clinical sig-
nificance of the above finding remains to be determined.
Of note, using the CD-EPI compared with the MDRD
equation also did not improve the number of subjects
correctly classified to CKD stage 1 or stage 2. Overall
both the CKD-EPI and MDRD equations displayed poor
precision. For example, the overall mGFR of the patient
population was 80 ml/min/1.73 m2 and the SD of the
bias was 16.6 ml/min/1.73 m2 for an eGFR derived from
the MDRD equation. Hence, there would be 95 % prob-
ability of eGFR value being between 46 and 113 ml/min/
1.73 m2. Similarly, for an eGFR derived from the CKD-
EPI equation (SD of the bias 14.6 ml/min/1.73 m2), there
would be 95 % probability of an eGFR value being be-
tween 51 and 109 ml/min/1.73 m2.
We attempted to address the mechanisms that explain
why the CKD-EPI equation underestimates mGFR in the
normal to high range to the same extent as the MDRD
equation in people with diabetes. An analysis of patient
characteristics such as age, sex, BMI, HbA1c levels, fast-
ing plasma glucose values and type of diabetes, before
and after stratification for mGFR values, failed to reveal
any clear differences in eGFR values derived from the
MDRD or CKD-EPI equations. Any relationships that
we found between eGFR values derived either by the
MDRD or CKD-EPI equations and the clinical character-
istics of our study population are most likely explained
by the expected relationship between age, glucose con-
trol and GFR. Overall, no clinical or biochemical param-
eter was found to account for the reasons why the CKD-
EPI equation does not have a reduced bias compared
with the MDRD equation in people with diabetes.
We found no relationship between BMI and estimates
of GFR derived for both formulas. One study has sug-
gested that the underestimation of mGFR by the MDRD
equation is greatest in obese subjects with diabetes but
this finding has been called into question as obese sub-
jects in the above study had higher mGFR values com-
pared to non-obese subjects [20]. Any difference in bias
could therefore have been related to GFR rather than
measures of obesity. In contrast, another study has
found that the CKD-EPI equation did not outperform
the MDRD equation in obese patients, with both equa-
tions mildly overestimating a directly measured GFR
value of 56 ml/min/1.7 m2 [21].
High plasma glucose levels are well known to be asso-
ciated with higher GFR levels [22–26]. Indeed we found
that mGFR levels were high in patients with fasting BSL
levels > 8 mmol/L compared to those with lower glucose
levels. Recently, higher blood glucose levels have been
associated with higher GFR values derived from serum
cystatin C levels [27]. Whilst acute fluctuations in glu-
cose levels may influence GFR and make the estimation
of a patient’s true baseline GFR difficult to determine,
we found that eGFR values derived from the CKD-EPI
or the MDRD equations were similar for patients with
Table 3 Summary of bias, precision and accuracy of the MDRD
and CKD-EPI equations compared to mGFR-CKD stage 1: ≥ 90,
stage 2: 60-89 and < stage 3: < 60 ml/min/1.73 m2. Bias = eGFR-
mGFR, precision = SD of the bias and accuracy = the proportion
of results falling within 15 % or 30 % of mGFR values
MDRD Bias P(15) P(30)
GFR >90 ml/min/1.73m2 (n=76) -11.0 ± 18.3 47.4 % 89.5 %
GFR 60-90 ml/min/1.73m2 (n=63) +3.8 ± 14.3 58.7 % 79.4 %
GFR <60 ml/min/1.73m2 (n=60) +4.6 ± 1.0 43.3 % 83.3 %
p value <0.001 0.06 0.57
CKD-EPI Bias P(15) P(30)
GFR <90 ml/min/1.73m2 (n=76) -12.4 ± 12.2 69.7 % 97.4 %
GFR <60-90 ml/min/1.73m2 (n=63) +5.0 ± 11.9 57.1 % 87.3 %
GFR <60 ml/min/1.73m2 (n=60) +5.3 ± 10.8 40.0 % 78.3 %
p value <0.001 0.002 0.001
* P < 0.05 vs MDRD
mGFR measured Glomerular Filtration Rate, CKD chronic kidney disease, MDRD
modification of diet in renal disease, CKD-EPI Chronic Kidney Disease-
Epidemiology Collaboration, P(15) proportion of results falling within 15 % of
mGFR values, P(30) proportion of results falling within 30 % of mGFR values
Table 4 Classification of the study population into CKD stages based on mGFR according to the MDRD or CKD-EPI equation
CKD stage according to mGFR N Classification based on the MDRD formula Classification based on the CKD-EPI formula
Sensitivity Specificity Correctly classified Sensitivity Specificity Correctly classified
≥ 90 (Stage 1) 81 64.2 % 88.98 % 78.89 % 76.5 % 84.75 % 81.41 %
60-89 (Stage 2) 58 65.5 % 70.92 % 69.35 % 58.6 % 76.6 % 71.36 %
<60 (Stage ≤ 3) 60 80 % 94.96 % 90.45 % 76.7 % 95.68 % 89.95 %
mGFR measured Glomerular Filtration Rate, CKD chronic kidney disease, MDRD modification of diet in renal disease, CKD-EPI Chronic Kidney
Disease-Epidemiology Collaboration
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different fasting glucose levels. Therefore, whilst plasma
glucose levels can acutely influence GFR we did not find
evidence to suggest that plasma glucose levels differen-
tially affect an eGFR derived from the CKD-EPI com-
pared with the MDRD equation.
As expected we found that that older compared with
younger subjects had lower mGFR values but age had a
similar effect on eGFR values from the MDRD or the
CKD-EPI equations. Although we could not show that
sex had a differential effect on an eGFR value from the
MDRD or the CKD-EPI equations, we found that males
had lower eGFR values derived from the MDRD equa-
tion than females at mGFR levels > 90 ml/min/1.73 m2.
This may be due the MDRD equation not being able to
fully account for the expected higher serum creatinine
levels in males compared to females. No gender differ-
ences in eGFR values derived from the CKD-EPI formula
were observed.
Although the CKD-EPI equation may perform better
(less biased) than the MDRD equation in the general
population, this advantage over the MDRD equation for
estimating GFR is not as apparent in people with diabetes.
In a secondary analysis of the population originally used
to validate the CKD-EPI equation, the performance of the
CKD-EPI equation was examined according to level of
GFR and clinical characteristics (28 % with diabetes). The
overall conclusion of the study was that the CKD-EPI
compared with the MDRD equation substantially im-
proves bias in people with and without diabetes [5].
However, in the above study, eGFR values calculated
from the CKD-EPI equation underestimated measured
GFR values by 4.6 compared to only 1.3 ml/min/
1.73 m2, in people with and without diabetes, respect-
ively. This greater bias in people with diabetes was also
more pronounced when GFR was > 90 ml/min/1.73 m2.
In particular, for participants with diabetes and GFR
>90 ml/min/1/73 m2, eGFR values derived from the
CKD-EPI and MDRD equations underestimated mea-
sured GFR by 12.3 and 19.1.ml/min/1.73 m2, respectively
[5]. Reports of a lack of improvement in the underesti-
mation of GFR with the CKD-EPI equation compared
with the MDRD equation in people with diabetes and
normal to high GFR levels may therefore not be an un-
expected finding [6–10].
Of relevance to our findings, a decrease in the per-
formance of the CKD-EPI equation is being increasingly
recognised in people with diabetes compared to those
without diabetes. Camargo et al found that CKD-EPI
equation was less accurate in people with type 2 diabetes
when compared to healthy individuals [10]. One of the
limitations of that study was that serum creatinine levels
measured by the Jaffe reaction are possibly subject to
interference from plasma glucose levels and other chro-
mogens [28].
We have also recently demonstrated that when serum
creatinine is assayed by the gold standard enzymatic
method, the CKD-EPI equation also has greater bias in
Indigenous Australians with diabetes compared with
those without diabetes, especially in those with normal
to high renal function. In the above study, when mGFR
was > 90 ml/min/1.73 m2, an eGFR derived from the
CKD-EPI or MDRD equations underestimated measured
GFR by a similar extent, 7.4 and 7.2 ml/min/1.73 m2, re-
spectively [9]. One of the limitations of the above studies
was that they were cross sectional in design and did not
specifically examine the performance of the CKD-EPI
equation according to the clinical characteristics of par-
ticipants that had a direct measurement of GFR.
Our findings have significant implication for estimat-
ing renal function trajectories in people with diabetes.
Use to the CKD-EPI equation did not improve the
underestimation of the rate of decline in GFR from
normo-filtration to hypo-filtration that was observed
when eGFR was derived from the MDRD equation. This
significant underestimation of measured GFR trajector-
ies by the MDRD equation in subjects with type 1 dia-
betes has been previously reported by our group [15].
Currently, two large longitudinal studies have compared
rates of estimated with measured GFR decline over a
relatively short follow up interval of 3 to 4 years [8, 29].
One study has assessed the agreement of 15 creatinine
based formulas for estimating GFR with measured GFR
values (iohexol plasma clearance) in 600 patients with
type 2 diabetes with a baseline mGFR of 101 ml/min/
1.73 m2 in a cross-sectional analysis and in a longitu-
dinal analysis for 449 patients that had serial mGFR
measurements over 4 years (rate of GFR decline
-3.37 ml/min/1.73 m2). The overall agreement between
measured and all estimates of GFR was poor in both the
cross-sectional and the longitudinal analysis. In the en-
tire study population all 15 formulas underestimated the
rate of mGFR decline [8].
In a study of 997 patients with type 1 diabetes involved
in the Diabetes Control and Complications Trial/
(See figure on previous page.)
Fig. 3 The effects of age (≤60 or > 60 years), sex (male vs female), Body Mass Index (BMI) (≤30 or > 30 kg/m2), glycated haemoglobin (HbA1c)
(≤8 or > 8 % : ≤ 64 or > 64 mmole/mol), fasting plasma glucose (≤8 or > 8 mmol/L) or type of diabetes (type 1 or type 2) on mGFR and eGFR
values derived from the MDRD and CKD-EPI equations. *** p < 0.001 vs mGFR, ***p < 0.001 vs mGFR for age > 60 years, * P < 0.05 vs mGFR for
fasting plasma glucose≤ 8 mmol/L. mGFR: measured Glomerular Filtration Rate, MDRD: Modification of Diet in Renal Disease, CKD-EPI: Chronic
Kidney Disease-Epidemiology Collaboration
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Epidemiology of Diabetes Interventions and Complica-
tions (DCCT/EDIC) study who had direct measure-
ments of GFR (125Iothalamate urinary clearance) over a
mean interval duration of 3.1 years, changes in eGFR de-
rived from the CKD-EPI equation did not compare fa-
vorably with changes in mGFR. Although bias was small,
the correlation and precision of eGFR values derived
from the CKD-EPI formula were poor when compared
to mGFR values [29].
Cystatin C has been proposed as an alternative en-
dogenous marker of GFR to creatinine. The improve-
ment in accuracy for estimates of GFR based on cystatin
C compared with creatinine remains to be fully estab-
lished. Early studies based on estimating GFR from the
reciprocal value of serum cystatin C suggested that
cystatin C was less biased and provided a more accurate
method for estimating GFR values than creatinine based
methods when directly measured GFR is in the normal
to hyperfiltering range [12, 30–32]. The very large under
estimation of mGFR values that we observed with an
eGFR derived from the CKD-EPI equation emphasizes
that there is a need to improve estimates of GFR when
true GFR is in the hyperfiltering range.
However, more recent studies using cystatin C values
harmonized against an international reference standard
and the CKD-EPI 2102 cystatin equation have failed to
show that that estimating GFR based on cystatin C com-
pared with creatinine provides a substantial improvement
in accuracy [33]. The use of GFR estimating equations
based on a combination of serum cystatin C and creatin-
ine values may provide a more accurate way of estimating
GFR in routine clinical practice [33–35]. Unfortunately,
we did not have cystatin C values measured using a
harmonized assay to derive cystatin-eGFR or cystatin-
creatinine-eGFR values to allow a comparison of bias,
precision and accuracy with creatinine-eGFR or values in
the current study.
The limitations of this study, including the relatively
small number of participants, especially in the longitudinal
study and that the longitudinal study included only two
estimates of GFR for each participant are acknowledged.
Furthermore, in our longitudinal study, stored serum
Table 5 Patient characteristics for the longitudinal analysis (n= 30).
Values shown as mean ± SD or median (interquartile range)
Parameter All (n=30)
Age (yr) 48.2 ± 16.0
Gender (% males) 63
Type diabetes (% T1/T2) 70/30
Duration of diabetes (yr) 17.3 ± 9.7
Height (cm) 167.7 ± 12.2
Weight (kg) 74.0 ± 16.1
BMI (kg/m2) 26.3 ± 4.4
mGFR (ml/min/1.73m2) 102.8 ± 27.9
MDRD (ml/min/1.73m2) 83.6 ± 27.8
CKD-EPI (ml/min/1.73m2) 88.3 ± 25.2
AER (μg/min) 17.8 ± (10.3, 52.5)
AER (% normo/micro/macro) 54/33/13
HbA 1c (%) 8.8 ± 1.3
HbA 1c (mmol/mol) 73
Fasting blood glucose (mmol/L) 11.4 ± 6.1
Systolic blood pressure (mmHg) 137.4 ± 17.7
Diastolic blood pressure (mmHg) 78.8 ± 9.5
Any blood pressure therapy (%) 77
ACE inhibitor therapy (%) 43
Lipid lowering therapy (%) 73
Fenofibrate 0
Retinopathy (%) 40
IHD (%) 13
CVD (%) 13
PVD (%) 10
History of macrovascular disease (%) 43
BMI body mass index, mGFR measured Glomerular Filtration Rate, MDRD
modification of diet in renal disease, CKD-EPI Chronic Kidney Disease-
Epidemiology Collaboration, AER albumin excretion rate, Normo normoalbuminuria,
Micro microalbuminuria, Macro macroalbuminuria, HbA1c glycated haemoglobin,
ACE angiotensin converting enzyme, IHD Ischaemic Heart Disease, CVD
cerebrovascular disease, PVD peripheral vascular disease
Fig. 5 Longitudinal study of subjects with an early decline in GFR i.e.,
initial mGFR >60 ml/min/1.73 m2 and ΔmGFR ≥3.3 ml/min/1.73 m2
per year, ΔmGFR (based on initial and final values) was compared with
ΔeGFR by the CKD-EPI and MDRD equations over a mean of 9 years
(ANOVA: p = 0.01). *p < 0.05 vs mGFR. mGFR: measured Glomerular
Filtration Rate, MDRD: Modification of Diet in Renal Disease, CKD-EPI:
Chronic Kidney Disease-Epidemiology Collaboration
(See figure on previous page.)
Fig. 4 The effect of age, sex, BMI, HbA1c, fasting serum glucose levels and type of diabetes on eGFR values derived from the MDRD and CKD-EPI
equations across the different strata of mGFR. *p < 0.05 vs males with mGFR > 90 ml/min/1.73 m2. mGFR: measured Glomerular Filtration Rate,
MDRD: Modification of Diet in Renal Disease, CKD-EPI: Chronic Kidney Disease-Epidemiology Collaboration
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samples for re-assay were not available and estimates of
eGFR were based on creatinine levels that were stored on
our data base, and that were originally measured by the
Jaffe reaction. An attempt to harmonise theses historical
results with an enzymatic method was attempted but it is
appreciated that this approach has its limitations. Possibly,
longer studies that examine the relationship between
eGFR, measured GFR and multiple clinical and biochem-
ical variables at multiple time points in a prolonged longi-
tudinal study of people with and without diabetes will
help to delineate the reasons why the CKD-EPI equation
preferentially underestimated GFR in people with diabetes
.
Conclusions
In conclusion, in this study, both the CKD-EPI and
MDRD equations underestimate mGFR levels > 90 ml/
min/1.73 m2 by approximately 11 ml/min/1.73 m2. For
mGFR values > 120 ml/min/1.73 m2, the degree of
underestimation of GFR derived by the CKD-EPI equa-
tion was even more pronounced (23 ml/min/1.73 m2)
with no improvment in underestimation compared with
the MDRD equation. The mechanisms responsible for
the failure of the CKD-EPI equation to negate underesti-
mation of true GFR values in people with diabetes re-
mains unknown and does not appear to be explained by
patient characteristics such as age, sex, BMI, HbA1c or
fasting plasma glucose levels. We also found that using
the CKD-EPI compared with the MDRD equation does
increase the number of subjects with diabetes that are
correctly classified with having CKD stage 1. The under-
estimation of mGFR by the CKD-EPI equation has
significant implications for correctly identifying patients
with diabetes and GFR values in the normal and hyper-
filtering range and accurately following a possible subse-
quent decline in GFR. There is clearly a need to improve
estimates of GFR in people with diabetes who have GFR
values > 90 ml/min/1.73 m2.
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